GLP-1 users show lower 90-day sepsis mortality than SGLT2 inhibitor users

The wire

1. 01In type 2 diabetes patients who developed sepsis, prior GLP-1 receptor agonist use was linked to lower 90-day all-cause mortality than prior SGLT2 inhibitor use (48.6 vs 60.6 per 100 person-years; HR 0.81, 95% CI 0.75-0.88).
2. 02MACE (HR 0.77) and ICU admission (HR 0.89) remained significant after Holm correction; septic shock, acute respiratory failure and major adverse kidney events showed no difference.
3. 03Authors call the findings hypothesis-generating: retrospective design, class-level exposure definition, modest E-values and pre-matching imbalances leave residual confounding possible.

From the source

Prior Use of GLP-1 Receptor Agonists versus SGLT2 Inhibitors and Clinical Outcomes After Sepsis in Patients with Type 2 Diabetes: A Propensity Score-Matched Cohort Study

Drug design, development and therapy · 2026 · Liu HH, Huang SC, Wu JY et al.